Research
Hormonal
Dapagliflozin (10 mg daily) improves cardiometabolic outcomes in patients hospitalized for myocardial infarction, regardless of diabetes status, by reducing the risk of heart failure hospitalization and death.
If you have had a heart attack, even if you don't have diabetes, taking dapagliflozin (10 mg daily) alongside your standard heart medications can significantly improve your recovery outcomes. It reduces the risk of future heart failure hospitalizations and death. The benefit is seen regardless of your diabetes status.
StrongSupportsVERY_HIGH confidence
The DAPA-MI estimated trial duration was 30 months... The primary hierarchical seven-component composite outcome resulted in 32.9% wins for dapagliflozin and 24.6% wins for placebo (win ratio (WR) 1.34; 95% CI 1.20 to 1.50; p < 0.001)
Why this rating
Based on a randomized, placebo-controlled trial (DAPA-MI) with a hierarchical composite endpoint.
Source
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell et al. · Cardiovascular Diabetology · 2024
DOI 10.1186/s12933-024-02180-8
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (2.4 mg/weekly) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with overweight or obesity without diabetes, while also producing substantial weight loss and improving heart failure symptoms in those with preserved ejection fraction.Strong
- Bempedoic acid (180 mg daily) reduces major adverse cardiovascular events (MACE) in high-risk patients who are unable or unwilling to take statins, primarily by lowering LDL cholesterol and reducing coronary revascularization needs.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →